In a recent work we analyzed data from a large historic cohort of HER-2 positive early breast cancer patients treated with chemotherapy alone or with sequential trastuzumab at various Italian cancer centres between 1998 and 2011. This evidence concerns the gene ERBB2 and breast carcinoma.